Residual Risk of Adverse Kidney and Cardiovascular Outcomes in Patients with CKD.
作者信息
Khan Muhammad Shahzeb, Rashid Ahmed Mustafa, Shafi Tariq, Rangaswami Janani, Cherney David Z I, Butler Javed
机构信息
Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, Texas.
Department of Cardiology, Baylor Scott and White Heart Hospital Plano, Plano, Texas.
出版信息
Clin J Am Soc Nephrol. 2025 Mar 1;20(3):451-454. doi: 10.2215/CJN.0000000588. Epub 2024 Dec 17.
Abstract
摘要
相似文献
1
Residual Risk of Adverse Kidney and Cardiovascular Outcomes in Patients with CKD.慢性肾脏病患者不良肾脏和心血管结局的残余风险
Clin J Am Soc Nephrol. 2025 Mar 1;20(3):451-454. doi: 10.2215/CJN.0000000588. Epub 2024 Dec 17.
2
Antioxidants for chronic kidney disease.用于慢性肾病的抗氧化剂。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008176. doi: 10.1002/14651858.CD008176.pub2.
3
Blood pressure targets for hypertension in people with chronic renal disease.高血压合并慢性肾脏病患者的血压目标。
Cochrane Database Syst Rev. 2024 Oct 15;10(10):CD008564. doi: 10.1002/14651858.CD008564.pub3.
4
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在患有早期（1 至 3 期）非糖尿病慢性肾脏病的成人中的应用。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
5
Dietary interventions for adults with chronic kidney disease.针对成年慢性肾病患者的饮食干预措施。
Cochrane Database Syst Rev. 2017 Apr 23;4(4):CD011998. doi: 10.1002/14651858.CD011998.pub2.
6
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study.晚期慢性肾脏病患者停用与继续使用二甲双胍：一项苏格兰全国性目标试验模拟研究
Am J Kidney Dis. 2025 Feb;85(2):196-204.e1. doi: 10.1053/j.ajkd.2024.08.012. Epub 2024 Nov 7.
7
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review.患有慢性肾脏病患者发生心血管疾病的风险与成本和医疗资源使用相关：来自系统文献回顾的证据。
Adv Ther. 2021 Feb;38(2):994-1010. doi: 10.1007/s12325-020-01607-4. Epub 2021 Jan 11.
8
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾脏病患者的HMG辅酶A还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
9
Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study.早期慢性肾脏病中蛋白尿对心血管结局的预后影响：一项队列研究
Heart. 2025 May 12;111(11):506-512. doi: 10.1136/heartjnl-2024-324988.
10
Antioxidants for adults with chronic kidney disease.抗氧化剂治疗慢性肾脏病成人患者。
Cochrane Database Syst Rev. 2023 Nov 2;11(11):CD008176. doi: 10.1002/14651858.CD008176.pub3.
本文引用的文献
1
Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.基于风险加速实施2型糖尿病和慢性肾脏病的指南指导药物治疗
Circulation. 2024 Apr 16;149(16):1238-1240. doi: 10.1161/CIRCULATIONAHA.123.068524. Epub 2024 Apr 15.
2
The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes.慢性肾病合并2型糖尿病患者心脏肾脏保护治疗的基础与四大支柱。
Nephrol Dial Transplant. 2023 Feb 13;38(2):253-257. doi: 10.1093/ndt/gfac331.
3
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.升阶梯治疗急性心力衰竭指南导向的药物治疗的安全性、耐受性和疗效（STRONG-HF）：一项多中心、开放标签、随机试验。
Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
4
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.改善糖尿病肾病患者的肾脏和心血管结局的残余风险：对病理生理学、机制的综述以及来自近期试验的证据。
Diabetes Obes Metab. 2022 Mar;24(3):365-376. doi: 10.1111/dom.14601. Epub 2021 Dec 1.
5
Time-Centered Approach to Understanding Risk Factors for the Progression of CKD.以时间为中心的方法来理解 CKD 进展的风险因素。
Clin J Am Soc Nephrol. 2018 May 7;13(5):693-701. doi: 10.2215/CJN.10360917. Epub 2018 Mar 30.
Zotero 插件